Hodgkin’s Lymphoma

Allogeneic stem cell transplant is a current treatment option for patients with refractory/relapsed classic Hodgkin’s Lymphoma, including those who have failed an autologous transplantation.

Hodgkin’s Lymphoma is one of the most curable forms of cancer. The National Cancer Institute reported the five-year Hodgkin’s Lymphoma survival rate was 69.9% in 1975 and 85.4% in 2009. This increase is due to advancements in high-dose salvage chemotherapy and stem cell transplants for relapsed patients. The occurrence of relapse after 10 years is rare.

Some variables can increase or decrease the chance of surviving Hodgkin’s Lymphoma. Some examples are general health at diagnosis, other medical conditions, and whether the cancer is recurrent or progressive.

Other factors that affect survival include, stage of disease, age, sex, response to treatment, albumin level, white blood cell count and lymphocyte count, low hemoglobin and subtype of Hodgkin’s Lymphoma.

Click Here to Read More About Hodgkin’s Lymphoma

Back to Commercial Opportunities>>